DK0662130T3 - Process for Preparation of Hepatocyte Growth Factor and a Cell Line - Google Patents

Process for Preparation of Hepatocyte Growth Factor and a Cell Line

Info

Publication number
DK0662130T3
DK0662130T3 DK93921471T DK93921471T DK0662130T3 DK 0662130 T3 DK0662130 T3 DK 0662130T3 DK 93921471 T DK93921471 T DK 93921471T DK 93921471 T DK93921471 T DK 93921471T DK 0662130 T3 DK0662130 T3 DK 0662130T3
Authority
DK
Denmark
Prior art keywords
met
hgf
preparation
antibody
substance
Prior art date
Application number
DK93921471T
Other languages
Danish (da)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0662130T3 publication Critical patent/DK0662130T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to use of a substance which prevents HGF/SF from binding with Met in the preparation of a medicament for use in a method of preventing tumor cell metastasis, wherein in said method, a tumor-bearing mammal is treated with an effective inhibiting amount of said substance. The substance can e.g. be a HGF/SF variant, HGF/SF mimetic or antibody or antibody fragment against HGF/SF, a Met variant, Met mimetic or antibody or antibody fragment against Met or a polyclonal antibody generated against a peptide sequence within the extracellular domain of Met. <IMAGE>
DK93921471T 1992-09-18 1993-09-15 Process for Preparation of Hepatocyte Growth Factor and a Cell Line DK0662130T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18
PCT/US1993/008531 WO1994006909A2 (en) 1992-09-18 1993-09-15 A method of preventing tumor metastasis

Publications (1)

Publication Number Publication Date
DK0662130T3 true DK0662130T3 (en) 1998-08-10

Family

ID=25483898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93921471T DK0662130T3 (en) 1992-09-18 1993-09-15 Process for Preparation of Hepatocyte Growth Factor and a Cell Line

Country Status (10)

Country Link
EP (2) EP0805203B1 (en)
JP (2) JP3553936B2 (en)
AT (2) ATE368738T1 (en)
AU (1) AU675968B2 (en)
CA (1) CA2144856A1 (en)
DE (2) DE69334159D1 (en)
DK (1) DK0662130T3 (en)
ES (1) ES2112997T3 (en)
GR (1) GR3026165T3 (en)
WO (1) WO1994006909A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0661993B1 (en) * 1992-09-16 1997-05-07 Genentech, Inc. Protection against liver damage by hgf
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (en) * 1995-10-24 2006-10-11 敏一 中村 Anticancer drug
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
WO2000025727A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
AU1598801A (en) * 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
AU7785401A (en) * 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
EP1592713A2 (en) * 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
SI1648998T1 (en) 2003-07-18 2015-01-30 Amgen Inc. Specific binding agents to hepatocyte growth factor
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
ZA200701656B (en) 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
PL1863519T3 (en) 2005-03-31 2014-03-31 Massachusetts Gen Hospital Modulating hgf/hgfr activity for treating lymphodema
ZA200710599B (en) 2005-04-15 2009-08-26 Genentech Inc HGF Beta chain variants
ATE517126T1 (en) 2006-03-20 2011-08-15 Seikagaku Kogyo Co Ltd THERAPEUTIC FOR RHEUMATOID ARTHRITIS
BRPI0709917A2 (en) 2006-03-30 2011-07-05 Novartis Ag compositions and methods of use for c-met antibodies
CN107739407B (en) 2010-03-10 2021-07-06 根马布股份公司 Monoclonal antibodies against c-MEt
ES2594493T3 (en) 2010-11-03 2016-12-20 arGEN-X BV Anti-c-Met antibodies
US9150613B2 (en) 2011-04-02 2015-10-06 Washington State University Hepatocyte growth factor mimics as therapeutic agents
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN107002119A (en) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists
BR112017005202A2 (en) 2014-09-16 2017-12-12 Symphogen As anti-met antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (en) * 1990-05-09 1998-08-06 敏一 中村 Liver cirrhosis treatment
CA2091700C (en) * 1990-09-14 2002-11-19 Jeffrey S. Rubin A non-mitogenic competitive hgf antagonist
ATE222603T1 (en) * 1992-05-18 2002-09-15 Genentech Inc HEPATOCYT GROWTH FACTOR VARIANT

Also Published As

Publication number Publication date
EP0662130B1 (en) 1997-11-26
EP0805203A1 (en) 1997-11-05
ATE368738T1 (en) 2007-08-15
JPH08504093A (en) 1996-05-07
WO1994006909A3 (en) 1994-05-26
AU4855593A (en) 1994-04-12
AU675968B2 (en) 1997-02-27
JP2004002440A (en) 2004-01-08
DE69315440D1 (en) 1998-01-08
CA2144856A1 (en) 1994-03-31
EP0805203B1 (en) 2007-08-01
ATE160585T1 (en) 1997-12-15
ES2112997T3 (en) 1998-04-16
JP3553936B2 (en) 2004-08-11
DE69315440T2 (en) 1998-07-09
GR3026165T3 (en) 1998-05-29
EP0662130A1 (en) 1995-07-12
DE69334159D1 (en) 2007-09-13
WO1994006909A2 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
DK0662130T3 (en) Process for Preparation of Hepatocyte Growth Factor and a Cell Line
DE69433406T2 (en) ANTIBODIES AGAINST CD40
NO2017038I1 (en) Adalimumab - Extended SPC
UA111707C2 (en) APPLICATION OF SELECTED HUMAN ANTIBODY ANTI-TNF-ALPHA
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
DE69233482D1 (en) Method for reducing the immunogenicity of antibody variable domains
BR9707819A (en) Peptide immunogens
ATE162079T1 (en) USE OF PREPARATIONS CONTAINING ANTIBODIES FOR IMMUNOSUPRESSION
DE69328928T2 (en) VARIANTS IN THE LELTIN DOMAIN BY SELEKTIN
ATE162553T1 (en) MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS
DK0504307T3 (en) Method of treating septic shock
DK361282A (en) PROCEDURE FOR THE PREPARATION OF O-ALKYL-O-CARBAMOYL GLYCEROPHOSPHOCHOLINES
DE69527868T2 (en) Monoclonal antibody against tumor cytotoxic factor II (TCF-II)
DK119891A (en) IMPROVEMENTS IN AND RELATED TO MAGNETIC RESONANCE IMAGE
FI924278A (en) BCRF1 ANTAGONISTER FOER SKOETSEL AV EPSTEIN-BARR VIRUSINFEKTIONER
KR960028933U (en) Bucket stopper for magnetization
Durand-Charre et al. Structure and Solidification Sequence of Alloyed White Cast Irons.(Synopsis)
DK159280A (en) PROCEDURE FOR MANAGING THE CONTRAST BY REPRODUCTION LIKE RASTER REPRODUCTION
ES2030342A6 (en) Procedure for obtaining an antigen source for immunohistological serodiagnosis of listeriosis
Gurjevitch Rasryschitelnoe b tscheloveke kak tajny
DK26393D0 (en) PROCEDURE FOR SURFACE TREATMENT OF ISAER GRADE CASTLE IRON
DE68901234D1 (en) MEDICINAL COMPOSITION FOR TREATING LUNG CLOSURE.